Goldman Sachs Downgrades Johnson & Johnson (JNJ) to Sell, Sees Limited Upside
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Sachs Upgrades Eli Lilly (LLY) to Neutral on New "Hope Trade"
October 9, 2012 7:01 AM EDTGoldman Sachs upgraded Eli Lilly (NYSE: LLY) from Sell to Neutral with a price target of $54.00 (from $42.00) saying the Sola data supports optionality trade.
New solanezumab data provides a backbone for the recent "hope trade," the firm notes.
"Our... More
